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Variation in the penetrance estimates for BRCA1 and BRCA2 mutation carriers suggests that other genetic polymorphisms may modify
the cancer risk in carriers. The RAD51 gene, which participates in homologous recombination double-strand breaks (DSB) repair in
the same pathway as the BRCA1 and BRCA2 gene products, is a candidate for such an effect. A single-nucleotide polymorphism
(SNP), RAD51-135g-c, in the 50 untranslated region of the gene has been found to elevate breast cancer (BC) risk among BRCA2
carriers. We genotyped 309 BRCA1/2 mutation carriers, of which 280 were of Ashkenazi origin, 166 noncarrier BC patients and 152
women unaffected with BC (a control group), for the RAD51-135g-c SNP. Risk analyses were conducted using COX proportional
hazard models for the BRCA1/2 carriers and simple logistic regression analysis for the noncarrier case–control population. BRCA2
carriers were also studied using logistic regression and Kaplan–Meier survival analyses. The estimated BC hazard ratio (HR) for
RAD51-135c carriers adjusted for origin (Ashkenazi vs non-Ashkenazi) was 1.28 (95% CI 0.85–1.90, P¼0.23) for BRCA1/2 carriers,
and 2.09 (95% CI 1.04–4.18, P¼0.04) when the analysis was restricted to BRCA2 carriers. The median BC age was younger in
BCRA2-RAD51-135c carriers (45 (95% CI 36–54) vs 52 years (95% CI 48–56), P¼0.05). In a logistic regression analysis, the odds
ratio (OR) was 5.49 (95% CI 0.5–58.8, P¼0.163). In noncarrier BC cases, carrying RAD51-135c was not associated with BC risk
(0.97; 95% CI 0.47–2.00). These results indicate significantly elevated risk for BC in carriers of BRCA2 mutations who also carry a
RAD51-135c allele. In BRCA1 carriers and noncarriers, no effect for this SNP was found.
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Carriers of a mutated BRCA1 or BRCA2 gene are at an increased
risk of breast (BC) and ovarian cancer (OC); however, penetrance
estimates differ in various study populations (Easton et al, 1995;
Struewing et al, 1997; Ford et al, 1998; Thorlacius et al, 1998).
Modification of the risk by other genes or environmental factors
clustering in families probably explains most of this difference.
Genes involved in DNA repair, especially those that interact with
the product of the BRCA1 or BRCA2 genes, are of particular
interest as cancer risk modifiers in BRCA1/2 mutation carriers.
Both BRCA1 and BRCA2 participate in DNA double-strand
break repair through homologous recombination (reviewed in
Venkitaraman, 2002). RAD51, a eukaryotic homologue of the
bacterial RecA protein, is essential for DSB repair. The three
molecules co-localise in mitotic and meiotic cells and in DNA foci
induced by irradiation. Phenotypic similarities of brca1-, brca2-
and rad51-deficient murine models, as well as gross chromosomal
rearrangements such as translocations and deletions, which are a
common feature of brca1/2 or rad51 null cells, suggest that they
function in a common pathway.
A single-nucleotide polymorphism (SNP), g-c, at position 135
of the untranslated region of the RAD51 gene has been reported
(Levy-Lahad et al, 2001; Wang et al, 2001). The biological effect of
this polymorphism is currently unknown. However, in two studies,
an elevated BC risk associated with the RAD51-135c allele was
reported in BRCA2 mutation carriers, but not in BRCA1 mutation
carriers (Levy-Lahad et al, 2001; Wang et al, 2001). A lower risk for
OC in BRCA2 carriers was also suggested by the larger study
(Wang et al, 2001). Recently, an opposite effect of reduced BC risk
was reported in a population of BRCA1-5382insC carriers who also
carry the RAD51-135c (Jakubowska et al, 2003). This polymorph-
ism was not associated with BC risk in a large case–control study
in noncarrier population (Kuschel et al, 2002).
In order to confirm these results, we assessed the effect of the
RAD51-135g-c polymorphism on BC risk in BRCA1/2 mutation
carriers and in noncarrier BC cases, mainly of Ashkenazi origin.
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Study population
Two populations were studied: (1) BRCA1/2 mutation carriers of
Ashkenazi and non-Ashkenazi origin and (2) noncarrier, BC
patients and a control group without cancer, of Ashkenazi origin.
Blood samples from 309 BRCA1/2 mutation carriers were collected
through two centres: 263 carriers were identified through the
oncology department and the cancer genetics clinic in the
Hadassah Medical Center in Jerusalem, Israel, and 46 through
the cancer genetics clinic at the Royal Marsden NHS Trust,
London, UK. Cases were tested on the basis of a family history of
breast and/or OC or on the basis of their Ashkenazi origin. All but
one of the cases from Jerusalem were carriers of one of the three
Ashkenazi founder mutations (145 cases: 185delAG in BRCA1,3 5
cases: 5382insC in BRCA1 and 82 cases: 6174delT in BRCA2). The
UK carriers included 17 carriers of Ashkenazi founder mutations
(one individual carried both a 185delAG and 6174delT) and 29
other mutations (22 in BRCA1;7i nBRCA2). Of the 309 carriers,
177 were affected with BC, 40 with OC and 17 had both cancers. In
all, 69 of the mutation carriers were unaffected. Clinical data were
unavailable for six of the carriers.
A total of 166 ‘noncarrier’ Ashkenazi Jewish BC patients were
ascertained through the oncology department in Hadassah over
the period of 1994–98. They were enrolled according to the same
protocol as the BRCA1/2 carriers, but were found to be negative for
carrying any of the three Ashkenazi founder BRCA1/2 mutations.
In all, 24 (14%) of the patients were diagnosed below age 40 years,
54 (33%) were aged 40–49 years and 88 (53%) were aged 50þ
years. Where data were available (111 noncarrier cases), 71 (64%)
reported a positive family history of BC. Thus, this series has a
higher frequency of early-onset cases and cases with a family
history than would be expected in the Ashkenazi population
overall.
The controls were 152 females who took part in an independent
study into the genetics of diabetes. All controls were cancer-free,
of Ashkenazi origin and aged above 56 years (mean age 69, range
56–92 years). All participants signed an informed consent
approved by the local institutional ethics committee or gave
permission for samples to be used in an anonymous way for
research purposes.
Genotyping
Genomic DNA was extracted according to standard protocols, and
used as a template for the PCR reaction. An SNP of g-ca t
position 135 in the untranslated region of the RAD51 gene was
analysed using two methods: the ABI/PE Biosystems Taqman
system and a standard PCR and digestion technique. Eight samples
including three positive for the RAD51-135c allele were genotyped
using both methods, the results were 100% concordant. By the
ABI/PE Biosystems Taqman method, PCR amplification was
carried out in a final volume of 25ml containing 25ng genomic
DNA, 900nM of each primer, 200nM FAM-labelled probe, 200nM
VIC-labelled probe and 12.5ml2  Universal PCR master mix (PE
Biosystems) containing optimised buffer components and Rox
reference dye. The primer sequences were as follows: forward 50-
gca gcc tcc tct ctc cag c-30; reverse 50-gct ggg aac tgc aac tca tct-30.
Probe sequences were 50-Fam-ccc caa cgc ccc tgg ctt ac -30 and 50-
Vic-caa cgc ccg tgg ctt acg ct-30. The PCR amplification cycles were
951C for 10min, followed by 40 cycles of 951C for 15s and 621C for
1min. Levels of FAM and TET fluorescence were determined and
allelic discrimination was done using the ABI 7700 Sequence
detector. By PCR and digestion (Levy-Lahad et al, 2001; Wang et al,
2001), a PCR product of 157bp containing the RAD51-135g-c
polymorphism was amplified using the primers, forward: 50-
tgggaactgcaactcatctgg-30 and reverse: 50-gcgctcctctctccagcag-3, in a
mixture containing 1.5mM MgCl2 at an annealing temperature of
531C. The wild-type allele is digested by MvaI, resulting in 86- and
71-bp products. This restriction site is missing in the polymorphic
c allele. The PCR products were separated on a 3.0% agarose gel
with 2ml(100ml)
 1 of ethidiume bromide.
Statistical analysis
The effects of RAD51 genotypes on BC risk in mutation carriers
were evaluated using a COX proportional hazards model.
Participants were followed up retrospectively from the date of
birth to several possible outcomes. The outcome in women
affected with BC was recorded as the age at first BC diagnosis.
Women unaffected with BC were censored at the date of OC
diagnosis, prophylactic surgery, date of last follow-up, or death.
Since the distributions of age and disease status, and potentially
the genotype distribution, were different in the Ashkenazi and
non-Ashkenazi populations, the analyses were adjusted for ethnic
origin. Although selection of participants is partly based on
outcome, this method of analysis was used previously for risk
estimation in carriers (Rebbeck et al, 1999; Levy-Lahad et al, 2001).
In our study (Kadouri et al, 2001) on the modifying effect of the
androgen receptor in BRCA carriers, we compared COX propor-
tional hazards models to a variant of the log rank designed to
overcome selection bias by comparison of outcome to expected
penetrance according to the literature. Since the estimated risks
were close in both methods, in the current paper we have used
COX proportional hazard models. The significant analysis by COX
proportional hazard models (association in BRCA2 carriers) was
also analysed using logistic regression analysis and Kaplan–Meier
survival analysis, the event was recorded as first BC diagnosis and
unaffected women were censored in the same way as for the COX
analysis.
Clinical data were not available for six individuals, and six
individuals could not be genotyped, so that in the final analysis 297
mutation carriers were included, 191 BC cases and 39 OC cases
(including one woman diagnosed simultaneously with both
cancers and therefore counted as affected with both cancers) and
67 unaffected carriers.
The case–control analyses based on the non-carrier BC cases
(n¼155) and controls (n¼142) were performed using a standard
logistic regression approach. All analyses were performed using
SPSS.
RESULTS
The RAD51-135c heterozygote frequency was 41 out of 303 (13.5%)
in all BRCA1/2 carriers, 35 out of 276 (12.7%) in the Ashkenazi
carrier population and six out of 27 (22.2%) in the British (non-
Ashkenazi) population (Table 1). No RAD51-135c homozygotes
Table 1 Frequencies of RAD51-135g/c alleles by disease status in
BRCA1/2 mutation carriers
Clinical presentation
All
a
(n¼297)
BRCA1
(n¼210)
BRCA2
(n¼86)
Breast cancer 22/124 (17.2%) 13/78 (16.2%) 9/46 (19.6)
Bilateral breast cancer 3/50 (6%) 3/43 (7%) 0/7 (0%)
Breast and ovarian cancer 2/17
b (11.7%) 1/12
c (8.3%) 1/5
d (20%)
Ovarian cancer 6/39 (11.7%) 6/27 (22.2%) 0/12 (0%)
Unaffected 8/67 (11.9%) 7/50 (14%) 1/16 (6.25%)
aIncluding one carrier of both 185delAG&6174delT mutations.
bIncluding three
individuals with bilateral BC and OC, of which one has RAD51-135c.
cIncluding two
individuals with bilateral BC and OC, of which one has RAD51-135c.
dIncluding one
individual with bilateral BC and OC.
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frequency between the two populations was not significant.
However, to control for this difference, risk analyses were adjusted
for origin, although the risk estimates changed very little with
adjustment. The frequency of RAD51-135c carriers according to
clinical presentation in BRCA1 and BRCA2 carriers is shown in
Table 1.
A similar frequency of RAD51-135c heterozygotes was found
among BC and unaffected BRCA1/2 carriers (14.1 and 13.2%,
respectively, Table 2). Among BRCA2 carriers, 10 out of 58 (17.2%)
affected with BC had the RAD51-135c allele, compared with one
out of 28 (3.6%) of the unaffected carriers (OC cases included;
Table 2). Frequencies in BRCA1 carriers were 12.8% (17 out of 133)
and 16.9% (13 out of 77) in BC cases and unaffected cases,
respectively. The estimated BC hazard ratio (HR) in BRCA1/2
carriers with the RAD51-135c allele (Table 2) was 1.28 (95% CI
0.85–1.90, P¼0.23). A significant effect was found when the
BRCA2 carriers were analysed separately (2.09, 95% CI 1.04–4.18,
P¼0.04). The average age at BC onset was similar in carriers of
both the g and c RAD51-135 genotypes (45.0 and 45.9 years;
Table 2); however, using Kaplan–Meier survival analysis, the
median time to BC development was 45 years (95% CI 36–54) in
BCRA2-RAD51-135c carriers and 52 years (95% CI 48–56) in the
BRCA2-RAD51-wt group (P
log rank¼0.0271, P
breaslow¼0.05). In a
logistic regression analysis, the estimated odds ratio (OR) adjusted
for origin and age was 5.49 (95%CI 0.5–58.8, P¼0.163). In BRCA1
carriers, no effect of the RAD51-135c was found (HR of 1.03, 95%
CI 0.62–1.72, P¼0.09). The estimation of RAD51-135g-c effect
on OC in BRCA1/2 carriers was limited by small numbers.
No effect for the RAD51-135c allele on BC risk was found in the
noncarrier case–control analysis. The frequency of RAD51-135c
allele was 11.3% (16 out of 142) in BC cases and 10.3% (16 out of
155) in controls. The estimated relative risk (RR) for BC was 0.97
(95% CI 0.47–2.00, P¼0.97, Table 2).
DISCUSSION
Our study of the modifying effect of the RAD51-135c-g
polymorphism confirms the findings of two previous studies. We
found about a two-fold elevated BC risk among BRCA2 carriers
with the RAD51-135c allele using COX proportional hazards
models. In Kaplan–Meier survival analysis, the median age at BC
development was significantly 7 years younger among BRCA2-
RAD51-135c, compared with BRCA2-RAD51-wt carriers. For
comparison, we also report the estimated OR by logistic regression
analysis, which was also elevated in BRCA2-RAD51-135c carriers;
however, this was nonsignificant. The BRCA2-RAD51-135c com-
prised only 11 cases rendering an unstable and nonsignificant OR
using this model. In addition, since the unaffected carriers are at a
substantial elevated lifetime risk for BC, using a simple case–
control analysis does not consider the age at onset in the affected
group, as well as the length of follow-up in the yet, unaffected
controls. The COX proportional hazard model takes into account
the time factor, and therefore maybe more suitable for risk
analyses in carriers.
Wang et al (2001) reported an odds ratio of BC of 3.2 (95% CI
1.4–4.0) based on a population of 216 BRCA2 carriers, carrying the
RAD51-135c; it was also associated with a younger age at BC onset.
The estimated HR associated with the RAD51-135c allele in a study
of 67 Ashkenazi BRCA2 carriers was 4.1 (P¼0.07; Levy-Lahad et al,
2001). Both studies, in agreement with our results, did not observe
an effect of the RAD51 genotype in BRCA1 carriers. Wang et al also
found reduced OC risk of 0.40–0.66 among BRCA2 and RAD51-
135c carriers, although this was nonsignificant. We could not
estimate the associated OC risk due to small numbers. In
noncarriers, no BC risk association was found. Interestingly, an
opposite effect of reduced BC risk in BRCA1-5382insC carriers who
also carry the RAD51-135c was recently reported (OR¼0.23; 95%
CI, 0.07–0.62; P¼0.0015, Jakubowska et al, 2003). This study
included individuals of Polish ancestry, with much larger
frequency of the RAD51-135c allele (17 and 37% in affected and
unaffected, respectively) compared to ours and previously
reported studies. The number of BRCA1-5382insC carriers in our
study was too small for separate analysis. However, if these results
are confirmed in additional and larger studies, the RAD51 is the
first modifier gene with opposite effects in BRCA1 compared in
BRCA2 mutation carriers.
The biological effect of the RAD51-135g-c SNP is currently
unknown; however, since a similar modifying effect has been seen
in three separate studies, it is likely that it is a real risk modifier in
BRCA2 carriers. The BRCA2 has a distal role in DNA repair
machinery (Davies et al, 2001). It directly interacts with the RAD51
protein through the BRC repeat domain and regulates the
formation of RAD51 nucleoprotein filaments, which are essential
for DNA repair through homologous recombination. However, the
direct function of BRCA1 in DSB repair is less clear, a more
proximal role in sensing and regulation of cellular response to
DNA damage has been suggested by several recent papers
(reviewed by Venkitaraman, 2002). The BRCA1–RAD51 complex
Table 2 Frequencies of RAD51-135g-c alleles by BC disease status and BC relative risk (RR) in BRCA1/2 carriers and noncarriers
Genotype BC 
a (n¼106) no. (%) BC+
b (n¼191) no. (%) Av. age at BC onset (year)
c Breast cancer HR (95% CI) P-value
Carriers
BRCA1/2
d (n¼297)
Rad51-135c 14 (13.2) 27 (14.1) 1.28 (0.85–1.9)
wt
e 92 (86.8) 164 (85.9) 1 0.23
BRCA1 (n¼210)
Rad51-135c 13 (16.9) 17 (12.8) 36.7 1.03 (0.62–1.72)
wt 64 (83.1) 116 (87.2) 41.9 1 0.09
BRCA2 (n¼86)
Rad51-135c 1 (3.6) 10 (17.2) 45.0 2.09 (1.04–4.18)
wt 27 (96.4) 48 (82.8) 45.9 1 0.04
Noncarriers (n¼155) (n¼142) BC RR (95% CI)
Rad51-135c 16 (10.3) 16 (11.3) 1
Wt 139 (89.7) 126 (88.7) 0.97 (0.47–2.00) 0.94
aBC+: affected with breast cancer.
bBC : unaffected with breast cancer.
cAverage age at breast cancer onset for individuals by RAD52-135 genotype.
dIncluding one carrier of
both 185delAG&6174delT mutations.
ewt: wild-type allele.
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molecule (Scully et al, 1997). Therefore, it is biologically plausible
that the effect of RAD51 SNP is different in BRCA2 compared with
BRCA1 mutation carriers, although the biochemical mechanism
remains to be determined.
Recently, the role of CHEK2, also part of the same pathway of
the double-strand DNA break repair machinery, was studied in BC
patients. The CHEK2 1100*delC, a truncating variant that impairs
the kinase activity of the protein, is associated with an increase of
BC risk in BRCA1/2-negative individuals with a family history (The
CHEK2-Breast Cancer Consortium., 2002; Vahteristo et al, 2002).
This variant conferred no increased cancer risk among BRCA1/2
carriers or sporadic cases (The CHEK2-Breast Cancer Consor-
tium., 2002). The authors suggest that the lack of effect in BRCA1/2
carriers is because these genes are part of the same pathway, which
is already nonfunctioning in BRCA1 or BRCA2 null cells. This
contradicts our finding of a modifying effect associated with the
RAD51-135c variant. Several possible reasons may account for this
controversy. Impaired function of some but not all the additional
proteins in a common pathway may be critical to carcinogenesis
before the loss of function of the wild-type BRCA1/BRCA2 allele,
while there is still a functioning BRCA1/BRCA2 protein. Alter-
natively, the type of genetic alteration may be important, for
example, a truncating mutation vs a modifying polymorphism. In
the case of the 6174delT mutation, which comprises the majority of
our BRCA2 carrier population as well as in the two before-
mentioned studies, part of the BRC repeat domains is still present.
Altered function of the RAD51 protein may affect the RAD51-
BRCA2
6174delT complex and sequester targets of action and further
impair the function of the other wild-type (wt) allele as well.
However, a truncated protein as in the case of the 1100*delC
variant may either allow the other wt protein a normal function
that results in a low effect on the phenotype of a BRCA1/2 mutant,
or as has been previously suggested, after the loss of the wt BRCA2
allele, an additional truncated protein would have no effect. Only
elucidating the biological basis of the RAD51-135g-c polymorph-
ism can provide answers to this controversy.
In the present study, we have reported a modifying effect for the
RAD51-135g-c SNP in BRCA2 carriers, similar to the effect
reported in two previous studies. This is the first modifier gene
identified in BRCA2 carriers. The clinical implication of these
findings is still limited; however, it hints at differences in
molecular mechanisms involved in tumour development in BRCA1
and BRCA2 carriers. The study of polymorphisms in other DNA
repair genes could further elucidate the mechanism of tumorigen-
esis in BRCA1 and BRCA2 carriers.
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